Ezetimibe (Schering-Plough).
Copyright policy )Ezetimibe (Schering-Plough).
Ezetimibe (Sch-58235) is a cholesterol absorption inhibitor being developed by Schering-Plough for the potential treatment of atherosclerosis and hypercholesterolemia. By January 2000, it was in phase III trials in the US [353762], [363364]. Schering-Plough is studying ezetimibe as a monotherapy for lowering lipid levels and, by February 2000, it was also planning combination studies with commonly used statin (HMG-CoA reductase inhibitor) therapies. The company believes that ezetimibe will have additive effects with the statins, inhibiting the absorption of cholesterol in the intestine while the statins work by inhibiting the production of cholesterol in the liver [363364]. In May 2000, Merck signed an agreement with Schering-Plough to develop and market in the US a once-daily, fixed-combination tablet with simvastatin (Zocor) [368021]. This combination has been shown to improve LDL reduction to 52% as compared to 35% with Zocor alone [375966].
Arteriosclerosis, Hypercholesterolemia, Drug Evaluation, Preclinical, Down-Regulation, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Animals, Bile, Humans, Intestinal Mucosa, Clinical Trials, Phase I as Topic, Contraindications, Anticholesteremic Agents, Cholesterol, LDL, Drugs, Investigational, Ezetimibe, Drug Combinations, Cholesterol, Clinical Trials, Phase III as Topic, Intestinal Absorption, Azetidines, Drug Therapy, Combination, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Forecasting
Arteriosclerosis, Hypercholesterolemia, Drug Evaluation, Preclinical, Down-Regulation, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Animals, Bile, Humans, Intestinal Mucosa, Clinical Trials, Phase I as Topic, Contraindications, Anticholesteremic Agents, Cholesterol, LDL, Drugs, Investigational, Ezetimibe, Drug Combinations, Cholesterol, Clinical Trials, Phase III as Topic, Intestinal Absorption, Azetidines, Drug Therapy, Combination, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Forecasting
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!